Survival Prolongation by Rationale Innovative Genomics

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped The SPRING trial had to be early terminated at the end of the Phase 1 portion of the study due to the absence of funding necessary for the performance of the Phase 2.

Conditions

Non-small Cell Lung Cancer Metastatic
Non-small Cell Lung Cancer Stage IIIB

Interventions

DRUG: Avelumab
DRUG: Axitinib
DRUG: Palbociclib

Sponsor

Worldwide Innovative Network Association

Collaborators

[object Object]
[object Object]